



Diosmin

Description

Diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources or derived from the flavonoid hesperidin. Diosmin was first isolated in 1925 from *Scrophularia nodosa*, and first introduced as a therapeutic agent in

1969. Diosmin is considered to be a vascular-protecting agent used to treat chronic venous insufficiency, hemorrhoids, lymphedema, and varicose veins. As a flavonoid, diosmin also exhibits anti-inflammatory, free-radical scavenging, and antimutagenic properties.

Diosmin differs molecularly from hesperidin by the presence of a double bond between two carbon atoms in diosmin's central carbon ring. Diosmin can be manufactured by extracting hesperidin from citrus rinds, followed by conversion of hesperidin to diosmin. Diosmin has been used for more than 30 years as a phlebotonic and vascular-protecting agent, and has recently begun to be investigated for other therapeutic purposes, including cancer, premenstrual syndrome, colitis, and diabetes.

Biochemistry and Pharmacokinetics

Flavonoids are a large group of plant pigments sharing the same basic chemical structure; i.e., a three-ringed molecule with hydroxyl (OH) groups attached. Diosmin (C₂₈H₃₂O₁₅) occurs naturally as a glycoside, meaning it has a sugar molecule attached to its three-ringed flavonoid structure.

Pharmacokinetic investigations have shown diosmin is rapidly transformed by intestinal flora to its aglycone form, diosmetin. Diosmetin is absorbed and rapidly distributed throughout the body with a plasma half-life of 26-43 hours. Diosmetin is degraded to phenolic acids or their glycine-conjugated derivatives and eliminated through the urine. Diosmin or diosmetin not absorbed is eliminated in the feces.^{1,2}

Mechanisms of Action

Diosmin's mechanisms of action include improvement of venous tone, increased lymphatic drainage, protection of capillary bed microcirculation, inhibition of inflammatory reactions, and reduced capillary permeability.³⁻⁶ Certain flavonoids, including diosmin, are potent inhibitors of prostaglandin E2 (PGE2) and thromboxane A2 (TxA2)⁷ as well as being inhibitors of leukocyte activation, migration, and adhesion. Diosmin causes a significant decrease in plasma levels of endothelial adhesion molecules and reduces neutrophil activation, thus providing protection against microcirculatory damage.^{8,9}

Clinical Indications

Varicose Veins/Chronic Venous Insufficiency

Chronic venous insufficiency is characterized by pain, leg heaviness, a sensation of swelling, and cramps, and is correlated with varicose veins. A multicenter international trial, carried out in 23 countries over two years, in which 5,052 symptomatic patients were enrolled, evaluated the efficacy of flavonoids in the treatment of chronic venous insufficiency. Patients were treated with 450 mg diosmin and 50 mg hesperidin daily for six months. Continuous clinical improvement was found throughout the study, as well as improvements in quality of life scores for participants.¹⁰

Diosmin-containing flavonoid mixtures have also been effective in treating severe stages of chronic venous insufficiency, including venous ulceration and delayed healing.^{3,5} In a randomized multicenter trial, 900 mg diosmin and 100 mg hesperidin plus standard venous ulcer management was compared with standard venous ulcer management alone. Standard ulcer management included cleaning, compression therapy, and skin care of the adjacent skin. Forty-seven percent of patients in the treatment group compared to 28 percent in the standard management group experienced complete healing of ulcers less than 10 cm in diameter.¹¹

Hemorrhoids

Several large clinical trials have demonstrated diosmin to be effective in the treatment of acute and chronic symptoms of hemorrhoids. A double-blind, placebo-controlled study of 120 patients showed improvement of pain, pruritis, discharge, edema, erythema, and bleeding on examination.¹² The treatment group was given a flavonoid mixture (90% diosmin and 10% hesperidin) at a dose of two 500-mg tablets daily for two months.

The use of diosmin in the treatment of hemorrhoids associated with pregnancy did not adversely affect pregnancy, fetal development, birth weight, infant growth, or infant feeding. Pregnant women suffering from acute hemorrhoids were treated eight weeks before delivery and four

weeks after delivery. More than half of the women participating in the study reported relief from symptoms by the fourth day.¹³ Diosmin is non-mutagenic and does not have any significant effect on reproductive function.¹⁴

Lymphedema

Diosmin acts on the lymphatic system by increasing lymph flow and lymph oncotic pressure.^{15,16} A flavonoid mixture containing diosmin was used to treat upper limb lymphedema secondary to conventional therapy for breast cancer. Results showed improvement of symptoms and limb volume; the mean decrease in volume of the swollen limb reached 6.8 percent.¹⁶ In addition, lymphatic functional parameters assessed with scintigraphy were significantly improved. Animal studies of high-protein lymphedema, such as in burns and lung contusions, showed significant improvement with diosmin.¹⁷

Diabetes

Diosmin has been shown to improve factors associated with diabetic complications. Blood parameters of glycation and oxidative stress were measured in type 1 diabetic patients before and after intervention with a diosmin-containing flavonoid mixture. A decrease in hemoglobin A1c was accompanied by an increase in glutathione peroxidase,¹⁸ demonstrating long-term decreased blood glucose levels and increased antioxidant activity.

Diosmin can normalize capillary filtration rate and prevent ischemia in diabetics. Rheological studies of type 1 diabetics show diosmin can facilitate hemorheological improvements due to decreased RBC aggregation, which decreases blood flow resistance, resulting in reduction of both stasis and ischemia.¹⁹⁻²¹

Cancer

Diosmin has been investigated in a number of animal models and human cancer cell lines, and has been found to be chemopreventive and antiproliferative.²²⁻²⁶ More clinically oriented research in this area is warranted to determine effective dosages and protocols.

Other Clinical Indications

Studies have also investigated the use of diosmin for stasis dermatitis,³ wound healing,²⁷ premenstrual syndrome,²⁸ mastodynia,^{29,30} dermatofibrosclerosis,³ viral infections,³¹ and colitis.³² More clinically oriented research is indicated.

Drug-Nutrient Interactions

Diosmin can cause a decrease in RBC aggregation and blood viscosity.¹⁹ There are no documented cases of adverse interactions between diosmin and prescription medications, but caution should be taken when combining diosmin with aspirin or other blood-thinning medications.

Data suggest that diosmin has an inhibitory effect on cytochrome P450-mediated metabolism in healthy volunteers, which may alter the pharmacokinetics of drugs taken concomitantly. Patients given metronidazole after nine days of pretreatment with 450 mg diosmin demonstrated changes in serum concentrations of metronidazole, as well as changes in urinary concentrations of metronidazole and its metabolites compared to controls.³³

Side Effects and Toxicity

In animal studies, a flavonoid mixture containing 90-percent diosmin and 10-percent hesperidin had an LD₅₀ of more than 3g/kg. In addition, animal studies have shown the absence of acute, subacute, or chronic toxicity after repeated oral dosing for 13 and 26 weeks using a dose representing 35 times the recommended daily dose.¹⁴

Diosmin is considered to have no mutagenic activity, embryo toxicity, nor any significant effect on reproductive function. Transplacental migration and passage into breast milk are minimal.¹⁴

Dosage

The standard dose of diosmin is 500 mg twice daily. For acute dosing, a loading dose of 1,000 mg three times daily for four days is recommended, followed by 1,000 mg twice daily for three days, and a maintenance dose of 500 mg twice daily for two months.

References

1. Cova D, De Angelis L, Giavarini F, et al. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. *Int J Clin Pharmacol Ther Toxicol* 1992;30:29-33.
2. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. *Drugs* 2003;63:71-100.
3. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. *Angiology* 2001;52:S49-S56.
4. Smith PD. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. *J Vasc Res* 1999;36:24-36.
5. Bergan JJ, Schmid-Schonbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. *Angiology* 2001;52:S43-S47.
6. Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. *Int J Microcirc Clin Exp* 1997;17:27-33.
7. Labrid C. Pharmacologic properties of Daflon 500 mg. *Angiology* 1994;45:524-530.
8. Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema. *Angiology* 2000;51:19-23.
9. Manthey JA. Biological properties of flavonoids pertaining to inflammation. *Microcirculation* 2000;7:S29-S34.
10. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized flavonoids. *Angiology* 2002;53:245-256.
11. Glinski W, Chodyncka B, Roszkiewicz J, et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicenter, controlled, randomized study. *Phlebology* 1999;14:151-157.
12. Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. *Angiology* 1994;45:574-578.
13. Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. *Int J Gynaecol Obstet* 1997;57:145-151.

14. Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. *Angiology* 1994;45:579-584.
15. Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). *Angiology* 1997;48:93-98.
16. Pecking AP. Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema. *Int Angiology* 1995;14:39-43.
17. Casley-Smith JR, Casley-Smith JR. The effects of diosmin (a benzo-pyrone) upon some high-protein oedemas: lung contusion, and burn and lymphoedema of rat legs. *Agents Actions* 1985;17:14-20.
18. Manuel Y, Keenoy B, Vertommen J, De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in type 1 diabetic patients. *Diabetes Nutr Metab* 1999;12:256-263.
19. Lacombe C, Bucherer C, Lelievre JC. Hemorheological improvement after Daflon 500 mg treatment in diabetes. *Int Angiol* 1988;7:21-24.
20. Lacombe C, Lelievre JC, Bucherer C, Grimaldi A. Activity of Daflon 500 mg on the hemorheological disorders in diabetes. *Int Angiol* 1989;8:45-48.
21. Valensi PE, Behar A, de Champvallins MM, et al. Effects of a purified micronized flavonoid fraction on capillary filtration in diabetic patients. *Diabet Med* 1996;13:882-888.
22. Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. *Eur J Nutr* 1999;38:133-142.
23. Yang M, Tanaka T, Hirose Y, et al. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. *Int J Cancer* 1997;73:19-24.
24. Tanaka T, Makita H, Kawabata K, et al. Modulation of N-methyl-N-amyl nitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination. *Carcinogenesis* 1997;18:761-769.
25. Tanaka T, Makita H, Kawabata K, et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. *Carcinogenesis* 1997;18:957-965.
26. Tanaka T, Makita H, Ohnishi M, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. *Cancer Res* 1997;57:246-252.
27. Hasanoglu A, Ara C, Ozen S, et al. Efficacy of micronized flavonoid fraction in healing of clean and infected wounds. *Int J Angiol* 2001;10:41-44.
28. Serfaty D, Mageron AC. Premenstrual syndrome in France: epidemiology and therapeutic effectiveness of 1000 mg of micronized purified flavonoid fraction in 1,473 gynecological patients. *Contracept Fertil Sex* 1997;25:85-90. [Article in French]
29. Meggiorini ML, Cascioli GL, Luciani S, et al. Randomized study of the use of synthetic diosmin in premenstrual and vascular dysplastic mastodynia. *Minerva Ginecol* 1990;42:421-425. [Article in Italian]
30. Ciardetti P, Zucconi G, Ottanelli S, Casparis D. Treatment of mastodynia with synthetic diosmin. *Ann Ostet Ginecol Med Perinat* 1985;106:258-266. [Article in Italian]
31. Bae EA, Han MJ, Lee M, Kim DH. *In vitro* inhibitory effect of some flavonoids on rotavirus infectivity. *Biol Pharm Bull* 2000;23:1122-1124.
32. Crespo ME, Galvez J, Cruz T, et al. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. *Planta Med* 1999;65:651-653.
33. Rajnarayana K, Reddy MS, Krishna DR. Diosmin pretreatment affects bioavailability of metronidazole. *Eur J Clin Pharmacol* 2003;58:803-807.